REQUEST A DEMO
Total
USD $0.00
Search more companies

Centro de Inmunologia y Genetica Cige S.A.S. (Colombia)

Main Activities: Ambulatory Health Care Services
Full name: Centro de Inmunologia y Genetica Cige S.A.S. Profile Updated: April 11, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Spanish Download a sample report

Centro de Inmunologia y Genetica Cige S.A.S. is a company based in Colombia, with its head office in Medellin. The company operates in the Ambulatory Health Care Services sector. Centro de Inmunologia y Genetica Cige S.A.S. was incorporated on September 04, 2018. There are currently 86 (2024) people employed by Centro de Inmunologia y Genetica Cige S.A.S.. In its most recent financial highlights, the company reported a net sales revenue increase of 108.93% in 2023. Over the same period, its total assets grew by 107.5%. In 2023, Centro de Inmunologia y Genetica Cige S.A.S.’s net profit margin decreased by 2.99%.

Headquarters
Calle 54 46 27 To Fundadores P8
Medellin; Antioquia;

Contact Details: Purchase the Centro de Inmunologia y Genetica Cige S.A.S. report to view the information.

Basic Information
Total Employees:
Purchase the Centro de Inmunologia y Genetica Cige S.A.S. report to view the information.
Outstanding Shares:
Purchase the Centro de Inmunologia y Genetica Cige S.A.S. report to view the information.
Incorporation Date:
September 04, 2018
Key Executives
Purchase this report to view the information.
Legal Representative
Company Performance
Financial values in the chart are available after Centro de Inmunologia y Genetica Cige S.A.S. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency COP. Absolute financial data is included in the purchased report.
Net sales revenue
108.93%
Total operating revenue
108.93%
Operating profit (EBIT)
78.27%
EBITDA
79.4%
Net Profit (Loss) for the Period
-79.26%
Total assets
107.5%
Total equity
6.91%
Operating Profit Margin (ROS)
-1.25%
Net Profit Margin
-2.99%
Return on Equity (ROE)
-26.85%
Debt to Equity Ratio
6.83%
Quick Ratio
0.08%
Cash Ratio
0.08%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?